Research programme: bacterial infections therapeutics - Vernalis

Drug Profile

Research programme: bacterial infections therapeutics - Vernalis

Alternative Names: BB 83815; BB 83857; BB 84234; BB 84416; BB 84518; BB 84887; BB 84888; BB 85035

Latest Information Update: 06 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Metalloprotease inhibitors; Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anthrax; Community-acquired pneumonia; Gram-positive infections

Most Recent Events

  • 14 Jan 2005 Discontinued - Preclinical for Anthrax in United Kingdom (unspecified route)
  • 14 Jan 2005 Discontinued - Preclinical for Community-acquired pneumonia in United Kingdom (IV)
  • 14 Jan 2005 Discontinued - Preclinical for Gram-positive infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top